Market Data
Market Cap₹17,128.3 Cr.
52W High₹1,737
Current Price₹1,236
52W Low₹1,231.25
Down from 52W High28.8 %
Face Value₹1
Performance
ROCE13.64 %
ROE16.5 %
EPS (TTM)₹10.28
EPS Prev Qtr₹20.6
EPS Last Year₹8.82
EBITDA Qtr₹224.15 Cr.
Book Value₹282
Financial Health
Debt/Equity0.59
Debt/Profit3.47
Total Assets₹7,365.51 Cr.
Dividend Yield0.58 %
Promoter Holding54.14 %
Earning Power11.66 %
Valuation
Stock P/E26.29
Industry P/E33.81
Price to Book4.39
Price to Sales5.3
Graham Number₹545.77
Key Metrics
Debt/Equity
0.64
Face Value
₹1
Interest Coverage
4.86
About ERIS Lifesciences Ltd
Healthcare · Pharmaceuticals
ERIS Lifesciences Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹1. Market cap ₹17,128.3 Cr.
Price Chart
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | - | 36.51 | ₹4,41,477.63 Cr | 0.87% | ₹12,172.7 Cr | - | ₹59,910.52 Cr | - | 18.72% | 0.05 |
| Divis Laboratories Ltd | - | 86.48 | ₹2,53,031.38 Cr | 0.31% | ₹2,925 Cr | - | ₹11,230 Cr | - | 23.04% | 0 |
| Torrent Pharmaceuticals Ltd | - | 77.67 | ₹1,85,216.32 Cr | 0.78% | ₹2,156 Cr | - | ₹15,723 Cr | - | 15.1% | 1.76 |
| Zydus Lifesciences Ltd | - | 27.01 | ₹1,20,897.46 Cr | 0.08% | ₹4,492.2 Cr | - | ₹28,591.7 Cr | - | 16.76% | 0.43 |
| Cipla Ltd | - | 33.28 | ₹1,12,201.64 Cr | 0.94% | ₹3,364.84 Cr | - | ₹28,324.4 Cr | - | 13.24% | 0.01 |
| Laurus Labs Ltd | - | 99.31 | ₹1,08,698.22 Cr | 0.06% | ₹1,090.76 Cr | - | ₹7,269.64 Cr | - | 20.79% | 0.45 |
| Dr Reddys Laboratories Ltd | - | 31.6 | ₹1,02,039.12 Cr | 0.65% | ₹3,183.3 Cr | - | ₹33,227.9 Cr | - | 10.05% | 0.17 |
| Mankind Pharma Ltd | - | 49.29 | ₹1,00,752.43 Cr | 0.04% | ₹2,067.57 Cr | - | ₹14,737.88 Cr | - | 13.95% | 0.38 |
| Aurobindo Pharma Ltd | - | 26.56 | ₹97,814.24 Cr | 0.24% | ₹3,710.8 Cr | - | ₹34,935.29 Cr | - | 12.75% | 0.2 |
| Lupin Ltd | - | 16.64 | ₹94,274.49 Cr | 0.87% | ₹5,550.99 Cr | - | ₹29,966.58 Cr | - | 27.95% | 0.26 |
| Glenmark Pharmaceuticals Ltd | - | 36.67 | ₹65,922.11 Cr | 0.11% | ₹1,797.81 Cr | - | ₹17,736.56 Cr | - | 24.78% | 0.25 |
| Alkem Laboratories Ltd | - | 28.65 | ₹61,804.34 Cr | 1.03% | ₹2,206.3 Cr | - | ₹15,081.28 Cr | - | 19.75% | 0.12 |
| Biocon Ltd | - | 110.29 | ₹61,113.53 Cr | 0.13% | ₹416.4 Cr | - | ₹17,321.1 Cr | - | 2.87% | 0.43 |
| Abbott India Ltd | - | 35.22 | ₹56,860.69 Cr | 1.78% | ₹1,614.68 Cr | - | ₹7,004.38 Cr | - | 45.73% | 0 |
| Glaxosmithkline Pharmaceuticals Ltd | - | 46.73 | ₹49,091.33 Cr | 1.97% | ₹1,068.15 Cr | - | ₹3,954.94 Cr | - | 64.07% | 0 |
| Ipca Laboratories Ltd | - | 36.13 | ₹48,712.48 Cr | 0.31% | ₹1,379.76 Cr | - | ₹10,125.58 Cr | - | 21.48% | 0.09 |
| Anthem Biosciences Ltd | - | 83.03 | ₹47,949.68 Cr | 0.23% | ₹575.95 Cr | - | ₹2,002.34 Cr | - | 25.5% | 0.02 |
| Gland Pharma Ltd | - | 42.26 | ₹47,764.08 Cr | 0.69% | ₹1,128.8 Cr | - | ₹6,725.3 Cr | - | 15.21% | 0.02 |
| Ajanta Pharma Ltd | - | 38.87 | ₹44,109.77 Cr | 0.79% | ₹1,134.88 Cr | - | ₹5,776.17 Cr | - | 31.81% | 0.05 |
| J B Chemicals & Pharmaceuticals Ltd | - | 53.3 | ₹38,730.77 Cr | 0.39% | ₹709.46 Cr | - | ₹4,147.79 Cr | - | 23.03% | 0 |
Quarterly Results
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Sales | 792.41 | 807.45 | 756.56 | 873.25 |
| ↳ QoQ Growth | - | +1.9% | -6.3% | +15.4% |
| Expenses | 573.28 | 596.18 | 552.56 | 649.1 |
| Operating Profit | 219.13 | 211.27 | 204 | 224.15 |
| OPM % | 27.65% | 26.17% | 26.96% | 25.67% |
| Other Income | 2.81 | 0.02 | 2.23 | 2.39 |
| Interest | 49.55 | 48.82 | 45.62 | 46.65 |
| Depreciation | 69.08 | 70.34 | 69.57 | 72.07 |
| EBITDA | 288.21 | 281.61 | 273.57 | 296.22 |
| EBITDA Margin % | 36.37% | 34.88% | 36.16% | 33.92% |
| Profit Before Tax | 172.67 | 145.35 | 159.41 | 179.49 |
| Tax % | 22.12% | 25.13% | -75.08% | 20.15% |
| Net Profit | 134.47 | 108.83 | 279.1 | 143.32 |
| ↳ QoQ Growth | - | -19.1% | +156.5% | -48.6% |
| EPS | 8.82 | 7.32 | 20.6 | 10.28 |
Balance Sheet
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 13.62 | 13.85 |
| Reserves | 2840.74 | 3888.82 |
| Borrowings | 2477.92 | 2309.68 |
| Other Liabilities | 1704.13 | 1153.16 |
| Total Liabilities | 7036.41 | 7365.51 |
| Fixed Assets | 662.07 | 5187.56 |
| CWIP | 66.74 | 171.47 |
| Investments | 67 | 61.56 |
| Other Assets | 6240.6 | 1944.92 |
| Total Assets | 7036.41 | 7365.51 |
Cash Flows
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Cash from Operating Activity | 1065.01 | 537.99 |
| Cash from Investing Activity | -79.97 | -369.46 |
| Cash from Financing Activity | -881.32 | -313.53 |
| Net Cash Flow | 103.72 | -145 |
Shareholding Pattern
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Promoters % | 54.85% | 54.85% | 53.92% | 54.14% |
| FIIs % | 7.21% | 6.85% | 6.39% | 5.75% |
| DIIs % | 19.36% | 20.32% | 20.35% | 20.72% |
| Public % | 9.12% | 8.51% | 10.06% | 10.1% |
| No. of Shareholders | 59,438 | 54,713 | 51,656 | 50,798 |
Major Shareholders (>1%)
- Amit Indubhusan BakshiPromoter and Promoter Group42.34%
- Lilac Investments LimitedPublic Shareholding8.63%
- Hdfc Small Cap FundPublic Shareholding8.33%
- Inderjeet Singh NegiPromoter and Promoter Group4.29%
As of 2026-06-30View all shareholders →